Clinical Features and Therapeutic Outcomes in Pyoderma Gangrenosum: A Prospective Cohort Study
JEADV Clinical Practice · 2026-06 · 5 (2) · 495-501
DOI: 10.1002/jvc2.70227 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift JEADV Clinical Practice, online erschienen am 28.11.2025. Verfasst von David Croitoru und 13 weiteren Autor:innen. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Canadian Dermatology Foundation.
Abstract (Originalsprache)
Background
Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis highly associated with systemic comorbidities. Accurate diagnosis and treatment remain challenging due to its rarity and clinical mimickers.
Objectives
To evaluate demographic, clinical features and treatment outcomes in patients referred with suspected PG at a tertiary wound care centre.
Methods
A prospective observational study was conducted of patients referred for suspected PG between April 2021 and June 2023. Demographic, clinical and laboratory data, including biopsies and tissue cultures, were collected. Patients were categorised as having PG vs alternative diagnoses based on diagnostic criteria from Su, Maverakis and the PARACELSUS score.
Results
Of 60 patients (female, 51.7%; mean [SD] age 52.9 [14.0] years), 44 (73.3%) met at least one published diagnostic criterion for PG. The most common comorbidity was IBD (63.6%), followed by inflammatory arthritis (25.0%) and monoclonal gammopathy of undetermined significance (MGUS) (4.5%). Systemic corticosteroids were used by 40.9% of patients before referral, but steroid‐sparing agents and biologics were the primary treatments after consultation. Biologics and steroid‐sparing agents were associated with significant improvement in disease activity using the PGA score (average score decreased from 2.3 to 1.5, p < 0.005), with 40.9% achieving complete remission. Elevated serum inflammatory markers and faecal calprotectin were observed in PG patients but absent in non‐PG cases.
Conclusions
These prospective data support previously published rates of association between PG and systemic comorbidities. Steroid‐sparing anti‐neutrophilic and targeted therapies are effective steroid‐sparing strategies in managing PG. Small sample size and referral bias may limit generalisability.
Förderung
- Canadian Dermatology Foundation
Zitieren
APA
Croitoru, D., Brahimi, N., Zabihi, H., Sibbald, C., Seigel, K., Shojaei, D., McMullen, E., Alavi, A., Archaempong, L., Drucker, A. M., Weizman, A., Croitoru, K., Inman, R., & Piguet, V. (2026). Clinical Features and Therapeutic Outcomes in Pyoderma Gangrenosum: A Prospective Cohort Study. JEADV Clinical Practice, 5(2), 495-501. https://doi.org/10.1002/jvc2.70227
Vancouver
Croitoru D, Brahimi N, Zabihi H, Sibbald C, Seigel K, Shojaei D, et al. Clinical Features and Therapeutic Outcomes in Pyoderma Gangrenosum: A Prospective Cohort Study. JEADV Clinical Practice. 2026;5(2):495-501. doi:10.1002/jvc2.70227
BibTeX
@article{Croitoru2026,
author = {Croitoru, David and Brahimi, Nesrine and Zabihi, Haleh and Sibbald, Cathryn and Seigel, Kyle and Shojaei, Delaram and McMullen, Eric and Alavi, Afsaneh and Archaempong, Lily and Drucker, Aaron M. and Weizman, Adam and Croitoru, Kenneth and Inman, Robert and Piguet, Vincent},
title = {Clinical Features and Therapeutic Outcomes in Pyoderma Gangrenosum: A Prospective Cohort Study},
journal = {JEADV Clinical Practice},
year = {2026},
volume = {5},
number = {2},
pages = {495--501},
doi = {10.1002/jvc2.70227}
}
EUVIMED